News

Filter

Current filters:

LicensingEisai

1 to 9 of 25 results

Helsinn grants Stendhal rights to NEPA in several Latin America countries

02-02-2015

Family-run Swiss oncology specialist Helsinn has granted exclusive rights to Mexico-based Especificos…

AkynzeoEisaiHelsinnLicensingNEPAnetupitantOncologypalonosetronPharmaceuticalSouth AmericaStendhal

Hikma to distribute Eisai’s Fycompa in Middle East

13-10-2014

Hikma Pharmaceuticals has entered into a partnership with Japanese pharma major Eisai for the distribution…

EisaiFycompaHikma PharmaceuticalsJordanLicensingMarkets & MarketingNeurologicalPharmaceuticalRest of the WorldSaudi Arabia

Eisai teams up with Zeria on proton pump inhibitor license agreement

Eisai teams up with Zeria on proton pump inhibitor license agreement

18-08-2014

Japanese drug major Eisai has collaborated with fellow Japanese company Zeria Pharmaceutical to conclude…

EisaiGastro-intestinalsJapanLicensingPharmaceuticalProton pump inhibitorsZeria Pharmaceuticals

Boston Strategics in-licenses Eisai’s cancer candidate E6201

01-07-2014

US clinical-stage drug R&D company Boston Strategics Corp has entered into an exclusive licensing and…

Boston Strategics CorpE6201EisaiLicensingOncologyPharmaceutical

Eisai expands deal with Biogen; re-files Fycompa with G-BA; news on Zebinix

Eisai expands deal with Biogen; re-files Fycompa with G-BA; news on Zebinix

12-05-2014

Japanese drug major Eisai has exercised its option to jointly develop and commercialize its clinical…

Biogen IdecEisaiFycompaGermanyItalyLicensingNeurologicalPharmaceuticalPricingRegulationZebinix

Otsuka acquires certain Dacogen and E7727 rights from Eisai

01-04-2014

Otsuka Pharmaceutical has reached an agreement with the US subsidiary of fellow Japanese drugmaker Eisai…

DacogenE7727EisaiLicensingOncologyOtsukaPharmaceutical

Eisai and Biogen Idec collaborate on Alzheimer’s disease treatments

Eisai and Biogen Idec collaborate on Alzheimer’s disease treatments

05-03-2014

US biotech firm Biogen Idec and Japanese drugmaker Eisai have entered into a collaboration to develop…

BAN2401BIIB037Biogen IdecBiotechnologyE2609EisaiLicensingNeurologicalResearch

Eisai takes over marketing authorization for Gliadel, and joins TB partnership

Eisai takes over marketing authorization for Gliadel, and joins TB partnership

25-11-2013

Japanese drug major Eisai (TYO: 4523) will become the Marketing Authorization Holder for the antineoplastic…

Antibiotics and Infectious diseasesAsia-PacificEisaiGliadelLicensingNobelpharmaOncologyPharmaceutical

1 to 9 of 25 results

Back to top